Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy

Shahneen Sandhu; Victoria Atkinson; María González Cao; Theresa Medina; Ainara Soria Rivas; Ivor Caro; Lewis R. Roberts; Yinghan Song; Yiyi Yan; Georgina V. Long

doi:10.1093/annonc/mdz255.046

Related publications

Article2022

Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti–programmed death-1 therapy

Shahneen Sandhu, Victoria Atkinson, María González Cao, Theresa Medina, Ainara Soria Rivas, Alexander M. Menzies, Ivor Caro, Louise Roberts, Yuyao Song, Yibing Yan, Guo Yu, Cloris Xue, Georgina V. Long

Article2016

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

Jeffrey R. Infante, Aaron R. Hansen, Michael J. Pishvaian, Laura Q.M. Chow, Grant A. McArthur, Todd M. Bauer, Stephen V. Liu, Shahneen Sandhu, Frank Tsai, Jeong Kim, Eric Stefanich, Chi‐Chung Li, Houston Gilbert, Bruce McCall, Maria Anderson, Mahrukh Huseni, Ina Rhee, Lillian L. Siu, Michael S. Gordon

Article2021

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, Alison M. Weppler, Allison Betof Warner, James R. Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L. Gérard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Célèste Lebbé, Paul Lorigan,

Article2020

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade

Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Masakatsu Tsurusaki, Naoshi Nishida

Article2016

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam, Victoria Atkinson, Annie Wong, John Park, Jennifer L. McQuade, Alexander N. Shoushtari, Katy K. Tsai, Zeynep Eroglu, Oliver Klein, Jessica C. Hassel, Jeffrey A. Sosman, Alexander Guminski, Ryan J. Sullivan, Antoni Ribas, Matteo S. Carlino, Michael A. Davies, Shahneen Sandhu, Georgina V. Long